KRAS and neoplasm: The aim of the current study was to develop a mathematical model to quantitatively characterize the dynamics of treatment response and evolving resistance, based on tumor sizes and mutant KRAS levels in ctDNA from metastatic colorectal cancer (mCRC) patients.